Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization and gene-knockout platforms. Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, show promise in prevention/treatment of cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy and graft versus host disease (GvHD) by neutralizing GM-CSF which is up-regulated in these conditions.



Pharmaceutical

Humanigen

Cameron Durrant

Yashmi Jogessar

henry madrid

Dale Chappell

The current leadership team at Humanigen has experience in a variety of industries, including healthcare, pharmaceuticals, and marketing. They have also received education from some of the top business schools in the world. This team is dedicated to providing the best possible products and services to their customers.

Leadership Team

About

Team members

Other teams at Humanigen

CEO and Executive Team

Board of Directors